spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:   bupivacaine 

 HSMN NewsFeed - 25 Sep 2024
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF(R) Vial Access Needle ("VAN")
Devices Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 26 Sep 2022
Innocoll and DURECT Announce U.S. launch of POSIMIR(R)
Biopharmaceuticals Drug Delivery Product Launch
 HSMN NewsFeed - 17 Mar 2022
Heron Therapeutics Announces Approval of ZYNRELEF(R) by Health Canada for the Management of Postoperative Pain
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 1 Jul 2021
Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF(TM) for the Management of Postoperative Pain for up to 72 Hours
Biopharmaceuticals Drug Delivery Product Launch
 HSMN NewsFeed - 13 May 2021
Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF(TM) (HTX-011) for the Management of Postoperative Pain for up to 72 Hours
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Feb 2021
DURECT Corporation Announces U.S. FDA Approval of POSIMIR(R) For Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 17 Jan 2020
DURECT Corporation Announces Outcome of FDA Advisory Committee Meeting for POSIMIR(R)
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 2 Oct 2019
DURECT Announces FDA Advisory Committee Meeting to Review POSIMIR(R) for the Treatment of Post-Surgical Pain
Biopharmaceuticals Drug Delivery Surgery FDA
 HSMN NewsFeed - 27 Jun 2019
DURECT Announces Submission to FDA of a Full Response to the POSIMIR(R) Complete Response Letter
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 26 Apr 2019
Aratana Therapeutics to be Acquired by Elanco Animal Health
Biopharmaceuticals Veterinary Mergers & Acquisitions
 HSMN NewsFeed - 31 Dec 2018
FDA Grants Priority Review Designation for Heron Therapeutics' NDA for HTX-011, a Non-Opioid for Postoperative Pain Management
Biopharmaceuticals Surgery FDA
 HSMN NewsFeed - 9 May 2018
DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR(R) (SABER(R)-Bupivacaine)
Biopharmaceuticals Drug Delivery Surgery Licensing
 HSMN NewsFeed - 22 Jun 2017
DURECT Completes Enrollment in PERSIST, Phase 3 trial for POSIMIR(R)
Biopharmaceuticals
 HSMN NewsFeed - 30 Dec 2016
Innocoll Receives Refusal to File Letter from U.S. FDA for XARACOLL(R) (bupivacaine HCl collagen-matrix implants) New Drug Application
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 12 Oct 2015
Heron Therapeutics Appoints Neil J. Clendeninn, M.D., Ph.D. as Senior Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Jan 2014
Impax and DURECT Sign a $63 Million Agreement to Develop and Commercialize DURECT’s ELADUR(R) Pain Patch
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 12 Nov 2013
A.P. Pharma Announces Pipeline Expansion
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 20 Jun 2013
DURECT Announces FDA Acceptance of New Drug Application (NDA) Submission for POSIDUR(R) (SABER(R)-Bupivacaine)
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 29 May 2013
Pacira Pharmaceuticals, Inc. Announces Positive Interim Analysis of EXPAREL in Femoral Nerve Block for Total Knee Arthroplasty
Biopharmaceuticals
 HSMN NewsFeed - 31 Oct 2011
Pacira Pharmaceuticals, Inc. Announces U.S. FDA Approval of EXPAREL(TM) For Postsurgical Pain Management
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Jan 2010
DURECT Initiates U.S. Pivotal Phase III POSIDUR(TM) Clinical Trial
Biopharmaceuticals
 HSMN NewsFeed - 31 Mar 2009
Innocoll, Inc. Files 510 (k) Application for CollaRx Lidocaine Sponge
Devices Wound Care
 HSMN NewsFeed - 17 Nov 2008
Innocoll Receives Fast Track Designation for Gentamicin Surgical Implant
Devices Drug Delivery FDA
 HSMN NewsFeed - 22 Sep 2008
Alpharma to Develop and Commercialize DURECT's ELADUR(TM) Pain Patch
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 15 Sep 2008
EpiCept Amends DURECT Bupivacaine Patch Licensing Agreement
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 25 Aug 2008
Baxter Announces Licensing Agreement for Innocoll's Gentamicin Surgical Implant in the United States
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 9 May 2008
EUSA Pharma Completes Acquisition Of Cytogen Corporation
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 11 Mar 2008
EUSA Pharma to Acquire US Specialty Oncology Company Cytogen
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 Feb 2008
ZARS Pharma Announces Marketing Authorization of Rapydan(R) in Europe
Biopharmaceuticals Regulatory Drug Delivery
 HSMN NewsFeed - 4 Jan 2008
Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
Devices Surgery Pain Management
 HSMN NewsFeed - 2 Jan 2008
Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
Devices Surgery
 HSMN NewsFeed - 18 Dec 2007
Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
Biopharmaceuticals Drug Delivery Wound Care
 HSMN NewsFeed - 17 Oct 2007
Innocoll Files Investigational New Drug Application for its CollaRx(R) BUPIVACAINE TOPICAL for the Treatment of Painful Chronic Skin Ulcers and Burns
Biopharmaceuticals Wound Care
 HSMN NewsFeed - 12 Sep 2007
Innocoll Enters Into Collaboration With TGR Biosciences for Development of a Novel Wound Healing Product
Biopharmaceuticals Drug Delivery Wound Care
 HSMN NewsFeed - 6 Sep 2007
Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Biopharmaceuticals Surgery Acquisitions
 HSMN NewsFeed - 6 Jun 2007
Innocoll Announces Filing of Investigational New Drug Application for its CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 24 Apr 2007
Innocoll Announces Outcome of FDA Meeting to Commence Phase 3 Development of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
Devices Surgery FDA
 HSMN NewsFeed - 4 Apr 2007
Innocoll Receives FDA Approval to Commence Phase 2 Clinical Development with its CollaRx(R) BUPIVACAINE IMPLANT for the Management of Post-operative Pain
Devices Surgery
 HSMN NewsFeed - 29 Mar 2007
Innocoll Files US and Irish Patent Applications for its CollaRx(R) BUPIVACAINE IMPLANT for the Management of Post-operative Pain
Devices Surgery
 HSMN NewsFeed - 8 Feb 2007
Polyanalgesic Consensus Panel Issues New Guidelines for Pain Management via Intraspinal Infusion
Biopharmaceuticals
 HSMN NewsFeed - 29 Jan 2007
DURECT Signs POSIDUR(TM) Manufacturing Agreement with Hospira
Biopharmaceuticals
 HSMN NewsFeed - 3 Jan 2007
DURECT Starts Phase II Dosing for TRANSDUR(TM)-Bupivacaine (DUR-843)
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 26 Dec 2006
EpiCept Licenses Patent for Bupivacaine in Back Pain to DURECT
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 29 Nov 2006
DURECT and Nycomed Sign $202 Million Agreement to Develop and Commercialize POSIDUR(TM) in Europe and Other Select Countries
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 12

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 12 additional stories matching:
bupivacaine
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.